Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Multi‐Institutional Analysis
International Journal of Urology · 2025
DOI: 10.1111/iju.70219 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Kotaro Suzuki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Nomograms, Prostatic Neoplasms, Castration-Resistant, Taxoids, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Cabazitaxel (CBZ) is the mainstay of treatment for metastatic castration‐resistant prostate cancer (mCRPC). In the present study, we developed a nomogram to predict the individual survival probability after CBZ treatment in patients with mCRPC.
Methods
We retrospectively analyzed 345 patients with mCRPC who started CBZ treatment between September 2019 and March 2024 and randomly divided them into a development cohort ( n = 230) and a validation cohort ( n = 115). We investigated several potential risk factors for poor overall survival (OS) using the Cox proportional hazard model and developed a nomogram to predict the 1‐year survival probability. The accuracy and discrimination ability of the nomograms were evaluated according to Harrell's concordance index (C‐index) and calibration plot.
Results
We developed a nomogram predicting the 1‐year survival probability with predictors including ECOG‐PS ≥ 2, presence of liver metastasis, an initial PSA ≥ 30 ng/mL, a PSADT ≤ 3 months, radiological progression of disease during docetaxel, Hb ≤ 12 g/dL, and LDH ≥ 250 U/L. C‐indices of our Cox hazard model at internal validation and external validation were 0.72 and 0.67, respectively. The model was adequately calibrated, and its predictions were correlated with the observed outcomes in both cohorts. The OS was significantly different among the risk groups defined by the total points calculated from the nomogram in both cohorts.
Conclusion
Our validated nomogram, which is predictive of the survival outcome after CBZ treatment in patients with mCRPC, may help in individual clinical decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Kotaro Suzuki, Junichiro Hirata, Hideto Ueki, Yasuyoshi Okamura, Takuto Hara, Tomoaki Terakawa, Yoji Hyodo, Jun Teishima
Zitieren
APA
Suzuki, K., Hirata, J., Ueki, H., Wakita, N., Okamura, Y., Hara, T., Terakawa, T., Hyodo, Y., Chiba, K., Teishima, J., & Miyake, H. (2025). Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Multi‐Institutional Analysis. International Journal of Urology. https://doi.org/10.1111/iju.70219
Vancouver
Suzuki K, Hirata J, Ueki H, Wakita N, Okamura Y, Hara T, et al. Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Multi‐Institutional Analysis. International Journal of Urology. 2025. doi:10.1111/iju.70219
BibTeX
@article{Suzuki2025,
author = {Suzuki, Kotaro and Hirata, Junichiro and Ueki, Hideto and Wakita, Naoto and Okamura, Yasuyoshi and Hara, Takuto and Terakawa, Tomoaki and Hyodo, Yoji and Chiba, Koji and Teishima, Jun and Miyake, Hideaki},
title = {Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Multi‐Institutional Analysis},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70219}
}
EUVIMED